https://www.fh-partners.com/news-entries daily 0.75 2026-03-05 https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1460850614813-Y27BHS4A5PC2MFCK3Q9J/stock-photo-1619803-foxglove-digitalis-purpurea-flowers_cropped.jpg News Entries https://www.fh-partners.com/news-entries/2026/3/5/xylocor-appoints-john-tucker-as-president-and-chief-executive-officer monthly 0.5 2026-03-05 https://www.fh-partners.com/news-entries/2026/2/24/neurent-medical-announces-publication-of-positive-randomized-controlled-trial-results-for-the-neuromark-system monthly 0.5 2026-02-24 https://www.fh-partners.com/news-entries/2026/2/11/kqryt1jg0vo62al8ygb8faaayvw5f4 monthly 0.5 2026-02-11 https://www.fh-partners.com/news-entries/2026/1/20/exciva-raises-51-million-59m-in-series-b-funding-round monthly 0.5 2026-01-20 https://www.fh-partners.com/news-entries/2026/1/9/haemonetics-acquires-vivasure-medical-limited monthly 0.5 2026-01-09 https://www.fh-partners.com/news-entries/2025/12/11/mainstay-medical-announces-coverage-recommendation-from-the-international-society-for-the-advancement-of-spine-surgery-isass-for-reactiv8 monthly 0.5 2025-12-11 https://www.fh-partners.com/news-entries/2025/12/9/mmi-wins-fda-clearance-and-completes-first-us-clinical-use-of-robotic-microsurgical-dissection-instruments-with-symani monthly 0.5 2025-12-09 https://www.fh-partners.com/news-entries/2025/11/21/lynkuet-elinzanetant-approved-in-the-eu-for-the-treatment-of-moderate-to-severe-vasomotor-symptoms-associated-with-menopause-or-endocrine-therapy-for-breast-cancer monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2025/11/5/mmi-receives-ide-approval-from-fda-for-first-robotic-microsurgical-study-in-alzheimers-patients monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2025/10/24/bayers-lynkuet-elinzanetant-the-first-and-only-neurokinin-1-and-neurokinin-3-receptor-antagonist-receives-fda-approval-for-moderate-to-severe-hot-flashes-due-to-menopause monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2025/10/10/neuromark-treatment-for-chronic-rhinitis-demonstrates-durable-2-year-clinical-benefits monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2025/10/6/mmi-completes-worlds-first-robotic-microsurgical-intracranial-brain-surgery monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2025/7/21/corteria-pharmaceuticals-initiates-phase-2-trial-in-heart-failure-and-phase-1-trial-in-obesity-with-its-first-in-class-crf2-agonists monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2025/7/17/first-patient-dosed-in-xylocor-therapeutics-phase-2b-exact-2-trial-evaluating-xc001-for-the-treatment-of-coronary-artery-disease monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2025/6/24/priothera-secures-eur17-million-i-nov-funding-by-bpifrance-for-rare-blood-cancer-clinical-program monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2025/6/24/vivasure-medical-submits-pma-application-for-perqseal-elite-and-secures-expanded-venous-indication-in-europe monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2025/6/11/neurent-medical-announces-510k-clearance-of-its-next-generation-neuromark-system monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2025/6/3/priothera-strengthens-board-with-appointment-of-industry-veteran-dr-hans-menssen monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2025/5/8/priothera-appoints-dr-jens-hasskarl-as-chief-medical-officer-to-drive-late-stage-clinical-development-of-mocravimod-a-s1p-receptor-modulator-for-acute-myeloid-leukemia-aml monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2025/4/28/mainstay-medical-announces-exclusive-coverage-of-reactiv8-by-anthem-blue-crossblue-shield monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2025/4/22/vivasure-medical-receives-ce-mark-approval-in-europe-for-perqseal-elite-vascular-closure-system monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2025/3/11/neuromod-closes-10m-financing-to-accelerate-commercialisation monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2025/1/16/mainstay-medical-announces-positive-outcomes-from-landmark-restore-clinical-trial-of-reactiv8 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2025/1/7/xylocor-therapeutics-raises-675-million-in-series-b-financing-to-advance-clinical-development-of-novel-gene-therapy-in-cardiovascular-disease monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2024/10/29/vivasure-announces-positive-results-of-patch-ide-pivotal-study-indicating-safety-and-efficacy-of-perqseal-large-hole-closure-device monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2024/10/3/mainstay-medical-announces-new-icd-10-diagnosis-code-for-multifidus-dysfunction monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2024/9/26/neuromark-treatment-for-chronic-rhinitis-yields-significant-clinical-improvements monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2024/8/20/lenire-controlled-clinical-trial-results-published-in-nature-communications monthly 0.5 2025-11-23 https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/c343f1f6-064b-474b-8007-2e8823a8b4df/Lenire-TENT-A3-Infographic-2250x2250-EN-1.jpeg News Entries - Lenire Controlled Clinical Trial Results Published in Nature Communications - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.fh-partners.com/news-entries/2024/8/1/mmi-completes-worlds-first-robotic-preclinical-study-in-neurosurgery-with-symani-surgical-system monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2024/7/10/mainstay-medical-announces-receipt-of-european-and-australian-approvals-of-mri-labeling-on-reactiv8-restorative-neurostimulation-system monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2024/7/8/xylocor-therapeutics-and-smartcella-enter-into-license-agreement-for-use-of-the-extroducer-infusion-catheter-system-to-administer-novel-gene-therapy-xc001-to-the-heart monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2024/7/9/mmi-builds-global-momentum-with-multiple-distribution-agreements-and-regulatory-approvals monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2024/6/17/neuromods-fda-approved-lenire-device-now-a-treatment-option-for-29-million-us-veterans-with-tinnitus monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2024/6/6/neurent-medical-announces-publication-of-positive-long-term-results-from-study-on-chronic-rhinitis-treatment monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2024/5/2/xylocor-therapeutics-positive-exact-phase-2-data-for-xc001-simultaneously-presented-at-scai-2024-scientific-sessions-and-published-in-circulation-cardiovascular-interventions monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2024/4/16/vivasure-medical-announces-first-large-hole-venous-patient-treated-with-perqseal-elite-vascular-closure-system monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2024/4/8/mmi-receives-fda-authorization-to-commercialize-symani-surgical-system-in-the-us monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2024/3/26/corteria-pharmaceuticals-announces-initiation-of-phase-1-study-to-evaluate-crf2-agonist-cor-1167-for-treatment-of-worsening-heart-failure monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2024/3/20/mainstay-medical-announces-publication-of-the-first-neuromodulation-study-for-low-back-pain-with-5-year-follow-up monthly 0.5 2025-11-23 https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1710957253767-FMRMHXZAR6F9KHHN2XNJ/VAS_5_Year_002.jpg News Entries - Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1710957279506-IA1XDONWNBY0QSKMG2ZQ/ODI_5_Year_002.jpg News Entries - Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1710957291156-7NEJHDWKS2F9SSNMOJ6Y/5Q-5D-5L_5_Year_002.jpg News Entries - Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up https://www.fh-partners.com/news-entries/2024/3/13/mainstay-medical-announces-publication-of-clinical-results-comparing-older-patients-and-younger-patients monthly 0.5 2025-11-23 https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/15abf003-c64f-4065-812f-49efa91a7a8e/2024-03-13_16-25-52.png News Entries - Mainstay Medical Announces Publication of Clinical Results Comparing Older Patients and Younger Patients - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.fh-partners.com/news-entries/2024/2/26/mainstay-medical-announces-us125-million-equity-financing-transaction monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2024/2/21/mmi-raises-110-million-in-series-c-financing monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2024/2/13/mainstay-medical-announces-receipt-of-fda-approval-for-mri-labeling-on-reactiv8-restorative-neurostimulation-systemtm monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2024/1/8/inotrem-successfully-reaches-agreement-with-the-fda-for-a-phase-3-registration-trial-for-nangibotide-in-septic-shock monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2024/1/8/calypso-enters-into-agreement-to-be-acquired-by-novartis monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2024/1/5/corteria-pharmaceuticals-appoints-mark-pruzanski-as-chairman-of-its-board-of-directors monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/11/27/us-fda-grants-orphan-drug-designation-to-mocravimod-to-improve-the-outcome-of-allogeneic-hematopoietic-stem-cell-transplantation-allo-hsct-in-patients-with-hematologic-malignancies monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/11/14/vivasure-medical-announces-100th-patient-enrolled-in-us-pivotal-study monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/11/13/neurent-medical-announces-new-cpt-code-for-chronic-rhinitis-treatment-offering-significant-symptom-improvements monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/10/19/mmi-expands-global-footprint-with-entry-into-asia-pacific-market monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/9/26/mmis-symani-robotic-surgical-system-surpasses-500-clinical-procedures monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/9/7/corteria-pharmaceuticals-announces-a-65m-financing-to-advance-transformational-medicines-in-cardiovascular-diseases monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/8/29/mainstay-medical-announces-completion-of-enrollment-of-restore-clinical-trial-of-reactiv8-in-the-united-states monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/8/25/xylocor-therapeutics-presents-phase-2-data-highlighting-safety-and-efficacy-of-xc001-at-the-european-society-of-cardiology-esc-congress-2023 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/8/3/results-from-xylocor-therapeutics-phase-1-portion-of-exact-trial-of-xc001-for-cardiovascular-disease-published-in-circulation-cardiovascular-interventions monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/7/21/mainstay-medical-announces-publication-of-three-year-clinical-trial-data-from-post-market-clinical-follow-up-registry-of-reactiv8-in-the-united-kingdom monthly 0.5 2025-11-23 https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/84dcc8bf-9e70-4b72-b0b0-ab46a906c9b0/2023-07-21_10-28-21.png News Entries - Mainstay Medical Announces Publication of Three-Year Clinical Trial Data from Post-Market Clinical Follow-up Registry of ReActiv8® in the United Kingdom - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.fh-partners.com/news-entries/2023/7/18/xylocor-therapeutics-reports-sustained-results-in-12-month-extension-of-phase-2-exact-clinical-trial-of-xc001-novel-gene-therapy-for-refractory-angina monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/6/1/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/5/15/dualyx-raises-40-million-to-progress-treg-therapies-for-autoimmune-diseases-into-the-clinic monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/4/14/neuromod-devices-closes-30-million-financing-to-expand-availability-of-tinnitus-treatment-device-lenire monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/3/21/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/3/13/vivasure-medical-announces-fda-ide-approval-to-initiate-us-pivotal-study monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/3/7/fda-grants-lenire-tinnitus-treatment-device-de-novo-approval monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/2/3/neurent-medical-announces-limited-market-release-of-neuromark-system-to-treat-chronic-rhinitis monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/1/26/xylocor-therapeutics-reports-positive-topline-safety-and-efficacy-results-from-phase-2-exact-clinical-trial-of-xc001-novel-gene-therapy-for-refractory-angina monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/1/23/priothera-announces-first-patients-enrolled-in-pivotal-motrans-global-phase-2b3-study-with-mocravimod-as-an-adjunctive-and-maintenance-therapy-for-patients-with-aml-undergoing-allogeneic-hct monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2023/1/9/inotrem-receives-funding-from-the-crohns-amp-colitis-foundation-to-help-develop-new-therapeutic-approaches-in-inflammatory-bowel-disease-ibd monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/12/16/calypso-biotech-announces-first-patient-with-eosinophilic-esophagitis-dosed-in-anti-interleukin-15-il-15-monoclonal-antibody-caly-002-phase-1ab-trial-and-animal-poc-data-in-atopic-dermatitis monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/10/25/inotrem-announces-that-its-essential-phase-ii-study-for-the-treatment-of-critically-ill-covid-19-patients-meets-its-primary-and-key-secondary-endpoints monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/10/21/corteria-pharmaceuticals-strengthens-its-executive-leadership-team-board-of-directors-and-scientific-advisory-board monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/10/13/inotrem-announces-the-outcome-of-its-phase-ii-astonish-trial-in-septic-shock-patients-demonstrating-efficacy-of-nangibotide monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/9/30/mainstay-medical-announces-publication-of-three-year-patient-outcomes-data-from-reactiv8-b-clinical-trial-demonstrating-long-term-efficacy-of-reactiv8-restorative-neurostimulation monthly 0.5 2025-11-23 https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/228de11b-811f-4d16-a7a4-ddfb1223ee98/2022-09-30_16-54-54.png News Entries - Mainstay Medical Announces Publication of Three-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™ - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.fh-partners.com/news-entries/2022/9/30/united-kingdom-national-institute-for-health-and-care-excellence-nice-publishes-interventional-procedure-guidance-ipg-for-reactiv8-restorative-neurostimulation monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/7/20/medical-microinstruments-secures-75m-to-advance-robotic-microsurgery monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/6/30/ermium-therapeutics-extends-its-initial-63-m-funding-to-123-m-to-further-advance-breakthrough-auto-immune-disease-therapeutics monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/6/28/xylocor-therapeutics-achieves-target-enrollment-in-phase-2-exact-study-of-xc001-novel-gene-therapy-for-ischemic-heart-disease monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/6/13/clinical-mocravimod-data-in-hematological-malignancies-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplant-ahsct-presented-at-the-2022-eha-congress monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/6/1/priothera-receives-fast-track-designation-for-mocravimod-in-combination-with-allogeneic-hsct-for-post-remission-therapy-of-aml-patient monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/6/1/inotrem-announce-the-appointment-of-luke-beshar-as-chairman-of-board-of-directors monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/5/26/medical-microinstruments-launches-new-simulator-for-robotic-microsurgery monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/5/18/medical-microinstruments-announces-major-expansion-in-pisa-italy-to-support-growth monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/5/18/xylocor-therapeutics-announces-presentation-of-preliminary-clinical-data-from-phase-1-portion-of-the-exact-phase-12-study-of-xc001-novel-gene-therapy-for-refractory-angina-at-aats-and-asgct monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/5/17/vivasure-medical-announces-series-d-financing-to-advance-portfolio-of-perqseal-vessel-closure-devices monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/4/25/priothera-receives-fda-clearance-of-ind-to-start-phase-2b3-study-with-mocravimod-in-acute-myeloid-leukemia-aml-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplant-hsct monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/4/20/vivasure-medical-begins-clinical-evaluation-of-next-generation-perqseal-device monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/4/14/inotrem-and-the-crohns-amp-colitis-foundation-sign-a-rampd-collaboration-agreement-to-support-the-development-of-a-new-therapeutic-approach-in-inflammatory-bowel-disease-ibd monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/4/12/priothera-receives-first-regulatory-approvals-to-start-a-global-pivotal-study-with-mocravimod-in-acute-myeloid-leukemia-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplant monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/4/12/neuromod-establishes-global-commercial-leadership-team monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/3/4/priothera-fda-and-ema-grant-orphan-drug-designation-to-mocravimod-for-the-treatment-of-acute-myeloid-leukemia-aml-in-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplantation-hsct monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/3/1/abbvie-acquires-syndesi-therapeutics-strengthening-neuroscience-portfolio monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/2/23/priothera-enters-loan-agreement-of-175-million-with-the-european-investment-bank monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/1/11/xylocor-therapeutics-expands-leadership-team-with-accomplished-pharmaceutical-executives-to-accelerate-clinical-development-programs-and-drive-corporate-growth monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/1/14/neuromod-launches-tologie-to-provide-specialist-care-service-for-tinnitus-patients monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2022/1/7/mainstay-medical-announces-publication-of-two-year-patient-outcomes-data-from-reactiv8-b-clinical-trial-demonstrating-long-term-efficacy-of-reactiv8-restorative-neurostimulation monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/12/14/mainstay-medical-announces-appointment-of-jeffrey-dunn-and-eric-major-to-its-board-of-directors monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/11/25/priothera-appoints-elisabeth-kueenburg-md-as-chief-medical-officer monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/11/18/neurent-medical-receives-fda-clearance-for-neuromark-a-novel-multi-point-nerve-disruption-treatment-for-chronic-rhinitis monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/11/9/inotrem-appoints-dr-gregory-meiffren-as-project-director-for-its-antibody-based-rampd-program-targeting-chronic-inflammatory-diseases monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/10/27/neuromod-appoints-teri-minard-to-lead-introduction-of-tinnitus-treatment-medical-device-to-us-veterans monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/10/21/syndesi-therapeutics-announces-commencement-of-dosing-in-clinical-trial-of-sdi-118-in-elderly-subjects-with-cognitive-impairment monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/9/13/neuromod-appoints-eric-timm-as-us-chief-executive-officer monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/9/9/calypso-biotech-announces-first-patient-with-celiac-disease-dosed-in-anti-interleukin-15-il-15-monoclonal-antibody-caly-002-phase-1b-trial-and-extension-of-series-a-to-28m monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/8/26/neuromod-establishes-us-presence-adds-local-leadership monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/8/16/neuromod-appoints-us-hearing-aid-industry-expert-and-audiologist-susan-whichard-to-company-board monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/8/10/lymphovenous-anastomosis-and-lymph-node-transfer-performed-with-medical-microinstruments-symani-surgical-system-at-the-renowned-university-hospital-zurich monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/7/26/xylocor-therapeutics-commences-phase-2-component-of-phase-12-exact-clinical-study-of-xc001-gene-therapy-for-refractory-angina monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/7/22/medical-microinstruments-announces-first-commercial-installation-of-the-symani-surgical-system monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/7/15/vivasure-medical-announces-development-of-sutureless-venous-closure-device-for-use-in-percutaneous-transcatheter-procedures monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/7/13/neuromod-research-reveals-that-more-than-three-in-four-uk-tinnitus-sufferers-have-never-received-treatment-for-their-condition monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/7/13/medical-microinstruments-symani-surgical-system-saves-patients-arm-from-amputation monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/7/12/inotrem-receives-approval-to-expand-nangibotide-clinical-trial-in-critically-ill-covid-19-patients-and-receives-additional-public-funding-of-45-million monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/7/7/nerre-therapeutics-raises-20-million-in-a-series-b2-financing-round monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/6/30/mainstay-medical-announces-limited-commercial-launch-of-reactiv8-in-the-us monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/6/29/neurent-medical-expands-leadership-team-to-support-advancement-of-in-office-chronic-rhinitis-treatment monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/6/22/inotrem-adds-a-new-strategic-asset-to-its-immunotherapy-anti-trem-1-drug-pipeline monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/6/10/inotrem-announces-positive-outcome-of-interim-futility-analysis-for-its-phase-iib-astonish-trial-in-septic-shock-patients-to-demonstrate-nangibotide-efficacy monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/4/20/vivasure-medical-begins-clinical-evaluation-of-next-generation-perqseal-device monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/3/24/inotrem-bolsters-leadership-team-with-the-appointment-of-sven-zimmermann-as-new-ceo monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/3/22/xylocor-therapeutics-completes-oversubscribed-419-million-series-a-financing-to-advance-novel-gene-therapy-pipeline-for-coronary-artery-disease monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/3/9/mainstay-medical-announces-commercial-launch-of-reactiv8-in-australia monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/2/16/mainstay-medical-announces-us108-million-equity-financing-transaction monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/1/27/syndesi-therapeutics-announces-positive-results-from-two-additional-phase-i-studies-of-its-novel-sv2a-modulator-sdi-118 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/1/26/mainstay-medical-announces-key-strategic-hires-to-drive-global-commercial-expansion monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/1/20/neurent-medical-closes-25-million-series-b-funding-to-advance-innovative-chronic-rhinitis-treatment monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2021/1/12/medical-microinstruments-appoints-healthcare-industry-veteran-mark-toland-as-chief-executive-officer monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/12/21/inotrem-announces-data-monitoring-committee-dmc-recommends-continuation-of-phase-iia-study-of-nangibotide-for-the-treatment-of-severe-forms-of-covid-19 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/11/2/fountain-healthcare-partners-announces-final-close-of-125-million-for-fund-iii monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/10/28/mmi-spa-launches-breakthrough-technology-advancing-robotic-microsurgery-with-the-worlds-smallest-wristed-surgical-instruments monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/10/20/neuromod-successfully-closes-105-million-series-b-financing-for-tinnitus-treatment-device-lenire monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/10/12/priothera-closes-30-million-series-a-financing-to-develop-highly-promising-therapies-for-acute-myeloid-leukemia-aml monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/10/8/neuromod-publishes-results-of-large-scale-tinnitus-clinical-trial-in-peer-reviewed-top-tier-scientific-journal monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/9/28/syndesi-therapeutics-progresses-development-of-sdi-118-for-cognitive-impairment-and-expands-its-series-a-financing monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/9/28/inotrem-expands-its-leadership-team-with-the-appointment-delphine-joyeux-as-director-of-regulatory-affairs-and-quality-assurance-and-of-simon-lambden-as-head-of-medical-science monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/9/21/inflazome-announces-acquisition-by-roche monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/8/10/bayer-to-acquire-uk-based-biotech-kandy-therapeutics-ltd monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/7/22/inotrem-receives-clearance-from-french-belgian-and-us-authorities-to-launch-a-phase-ii-clinical-trial-aimed-at-assessing-nangibotide-in-mechanically-ventilated-patients-with-covid-19 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/7/14/fda-grants-orphan-drug-designation-for-inflazomes-inzomelid-for-the-treatment-of-cryopyrin-associated-periodic-syndromes-caps monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/6/22/mainstay-medical-announces-us-fda-approval-of-reactiv8-neurostimulation-system-for-chronic-low-back-pain monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/6/8/mainstay-medical-announces-reimbursement-approval-for-reactiv8-in-australia monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/3/26/inzomelid-completes-phase-i-studies-and-shows-positive-results-in-the-treatment-of-cryopyrin-associated-periodic-syndrome-caps monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/3/11/neuromod-appoints-florian-elsaesser-as-chief-commercial-officer monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/2/27/inflazomes-somalix-demonstrates-positive-safety-tolerability-and-pharmacodynamic-profile-in-its-phase-i-study monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/2/10/inotrem-expands-series-b-financing-to-58-million-with-a-mix-of-equity-and-debt-adding-new-investors-fountain-healthcare-partners-kreos-and-bpi-france monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/1/13/inflazome-ip-portfolio-strengthened-with-patents-granted-in-us-and-europe monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2020/1/13/kandy-therapeutics-announces-positive-phase-2b-data-in-post-menopausal-women-with-its-lead-non-hormonal-product-nt-814 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/12/18/syndesi-therapeutics-announces-the-expansion-of-its-management-team-with-the-appointment-of-torsten-madsen-md-phd-as-chief-medical-officer monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/12/11/mainstay-medical-announces-completion-of-day-100-meeting-with-fda-regarding-pre-market-approval-pma-application-for-reactiv8 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/12/6/mainstay-medical-announces-regulatory-approval-from-australian-therapeutic-goods-administration-tga-for-reactiv8 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/11/7/inflazome-progresses-two-drugs-into-clinical-trials monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/11/5/syndesi-therapeutics-announces-successful-completion-of-first-in-human-phase-i-study-of-novel-sv2a-modulator-sdi-118-in-development-for-the-treatment-of-cognitive-impairment monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/10/1/mainstay-medical-announces-acceptance-for-filing-by-us-fda-of-pre-market-approval-pma-application-for-reactiv8 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/9/26/neuromod-successfully-closes-8-million-capital-raise monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/9/24/eib-unveils-financing-for-irish-innovation-as-galway-medtech-firm-vivasure-medical-gets-eur-10-million-backing monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/9/20/mainstay-medical-provides-company-update-and-reports-2019-half-year-financial-results monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/7/29/mainstay-medical-announces-completion-of-financing-transactions monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/6/26/mainstay-medical-announces-completion-of-pre-submission-meeting-with-fda-regarding-pre-market-approval-pma-application-for-reactiv8 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/6/7/nerre-therapeutics-announces-positive-findings-from-phase-2b-study-with-orvepitant-in-chronic-cough monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/5/23/fountain-healthcare-partners-raises-118m-for-third-fund monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/5/8/neuromod-broadens-senior-leadership-team-in-preparation-for-global-commercialisation-of-lenire-tinnitus-treatment monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/5/8/syndesi-therapeutics-announces-initiation-of-phase-i-study-of-novel-sv2a-modulator-sdi-118-in-development-for-the-treatment-of-cognitive-impairment monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/4/19/mainstay-medical-provides-company-update-and-publishes-2018-full-year-results monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/3/28/velicept-therapeutics-announces-positive-top-line-phase-2b-results-for-solabegron-in-the-treatment-of-overactive-bladder-oab monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/3/25/inflazome-receives-funding-from-the-michael-j-fox-foundation-for-parkinsons-research monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/3/20/syndesi-therapeutics-awarded-non-dilutive-funding-of-up-to-32m-for-development-of-its-lead-program-sdi-118-aimed-at-treating-cognitive-impairment monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2019/2/19/prof-marco-colonna-md-joins-inflazomes-scientific-advisory-board monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/12/11/kandy-therapeutics-announces-initiation-of-phase-2b-trial-of-nt-814-for-the-treatment-of-troublesome-post-menopausal-symptoms monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/12/3/mainstay-medical-to-showcase-reactiv8-and-key-clinical-data-at-the-13th-german-spine-congress-of-the-dwg monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/11/29/appointment-of-dr-thomas-jung-as-chief-medical-officer-of-inflazome monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/11/26/neuromod-appoints-leading-tinnitus-expert-professor-richard-s-tyler-phd-to-its-clinical-advisory-board monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/11/19/inflazome-completes-40m-46m-series-b-financing-to-develop-nlrp3-inflammasome-inhibitors-to-clinical-proof-of-concept monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/11/19/mainstay-medical-announces-headline-results-from-reactiv8-b-clinical-study monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/11/9/vivasure-medical-announces-launch-of-the-perqseal-large-bore-closure-device monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/10/31/validation-of-a-new-target-in-parkinsons-disease monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/10/25/opsona-therapeutics-ltd-to-present-results-on-tomaralimab-study-at-the-60th-annual-meeting-of-the-american-society-of-hematology-ash monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/10/16/velicept-therapeutics-raises-an-additional-15-million-in-series-b-round monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/10/9/syndesi-therapeutics-announces-appointment-of-roy-twyman-md-to-its-board-of-directors monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/10/4/kandy-therapeutics-presents-new-compelling-data-with-lead-candidate-nt-814-at-the-north-american-menopause-society-2018-annual-meeting monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/9/24/reduce-it-cardiovascular-outcomes-study-of-vascepa-icosapent-ethyl-capsules-met-primary-endpoint monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/9/21/mainstay-medical-announces-2018-half-year-financial-results-and-business-update monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/8/29/kandy-therapeutics-successfully-raises-25-million-in-a-series-c-financing monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/8/20/mainstay-medical-announces-the-appointment-of-matthew-onaitis-as-chief-financial-officer monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/7/9/mainstay-medical-announces-the-completion-of-all-implants-in-the-reactiv8-b-study monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/6/26/neuromod-welcomes-hearing-industry-leader monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/6/20/mainstay-medical-appoints-wolfgang-frisch-as-vp-and-managing-director-for-germany monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/6/7/kandy-therapeutics-announces-positive-clinical-data-with-lead-candidate-nt-814-for-the-treatment-of-symptoms-of-the-menopause monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/5/28/medical-device-company-neurent-medical-closes-93m-series-a-financing monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/5/15/syndesi-therapeutics-announces-appointment-of-jean-combalbert-as-chairman-of-the-board monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/4/18/medical-microinstruments-spa-announces-20m-in-series-a-funding-to-advance-its-robotic-platform-for-microsurgery monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/4/5/update-on-regulatory-application-for-reactiv8-in-australia monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/3/19/velicept-therapeutics-initiates-first-of-two-phase-2b-dose-ranging-studies-of-solabegron-in-patients-with-overactive-bladder-oab monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/2/28/syndesi-therapeutics-announces-appointment-of-experienced-management-team-to-lead-development-of-novel-pro-cognitive-sv2a-modulators monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/2/15/mainstay-medical-publishes-2017-full-year-results monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/2/15/mainstay-medical-announces-30-million-financing monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/2/1/chrono-therapeutics-announces-appointment-of-david-happel-as-chief-executive-officer monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/2/1/ucb-and-investor-syndicate-led-by-novo-seeds-launch-syndesi-therapeutics-to-develop-novel-therapeutics-for-cognitive-disorders monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/1/29/neuromod-announces-the-appointment-of-dr-hubert-lim-as-chief-scientific-officer monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2018/1/4/inflazome-appoints-renowned-harvard-cardiologist-to-its-scientific-advisory-board monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/12/11/mainstay-medical-announces-positive-outcome-of-interim-analysis monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/11/28/inflazome-appoints-renowned-scientific-industry-clinical-experts monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/10/16/vivasure-enrolls-first-patient-in-frontier-iv-clinical-trial monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/10/9/mainstay-medical-jason-hannon-joins-board-of-directors-begins-his-role-as-ceo monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/9/27/nerre-therapeutics-appoints-andrew-kay-as-chairman-of-the-board monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/9/27/kandy-therapeutics-launched-to-advance-a-breakthrough-treatment-in-womens-health monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/9/5/mainstay-medical-announces-half-year-financial-results monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/9/5/mainstay-medical-announces-ceo-leadership-transition monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/8/3/mainstay-medicals-reactiv8-b-clinical-trial-passes-mid-point monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/5/9/mainstay-medical-starts-commercialization-of-reactiv8-for-the-treatment-of-chronic-low-back-pain-in-ireland monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/4/10/codman-neuro-announces-acquisition-of-neuravi-limited-to-accelerate-innovation-in-acute-ischemic-stroke-therapy monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/4/5/gurnet-point-lp-enters-into-agreement-to-acquire-innocoll-holdings-plc monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/3/29/innocoll-announces-regulatory-path-forward-after-receiving-formal-fda-type-a-meeting-minutes-regarding-its-xaracoll-bupivacaine-hcl-collagen-matrix-implant-new-drug-application monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/3/23/mainstay-medical-publishes-2016-full-year-results-and-business-update monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/3/16/innocoll-holdings-plc-announces-fourth-quarter-and-full-year-2016-financial-and-operating-results-and-provides-corporate-update monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/3/16/innocoll-holdings-announces-statement-re-possible-offer monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/2/21/neuravi-announces-completion-of-patient-enrollment-in-clinical-trial-of-a-novel-stent-retriever-for-acute-ischemic-stroke monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/2/1/mainstay-medical-starts-commercialization-of-reactiv8-for-the-treatment-of-chronic-low-back-pain monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/1/12/mainstay-medical-applies-for-approval-to-market-reactiv8-in-australia monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2017/1/5/nerre-therapeutics-raises-23million-in-oversubscribed-series-b-financing-round monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/12/30/innocoll-receives-refusal-to-file-letter-from-us-fda-for-xaracoll-bupivacaine-hcl-collagen-matrix-implants-new-drug-application monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/12/20/opsona-therapeutics-ltd-announces-preliminary-results-from-ongoing-study-in-second-line-lower-risk-mds-recently-presented-at-the-58th-annual-ash-meeting monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/11/22/innocoll-holdings-plc-announces-third-quarter-2016-financial-and-operating-results-and-provides-corporate-update monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/11/22/opsona-therapeutics-ltd-to-present-preliminary-results-from-ongoing-study-in-second-line-lower-risk-myelodysplastic-syndrome-at-the-58th-annual-meeting-of-the-american-society-of-hema-7xjw3 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/11/3/innocoll-announces-top-line-data-from-phase-3-trials-with-cogenzia-and-nda-submission-for-xaracoll monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/11/2/neuravi-secures-15-million-to-fund-expansion monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/10/27/vivasure-medical-appoints-robert-chip-hance-to-companys-board-of-directors monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/10/26/mainstay-medical-announces-additional-us-patent-issued monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/10/25/opsona-therapeutics-ltd-receives-orphan-designation-for-myelodysplastic-syndrome-mds-with-opn-305-a-first-in-class-monoclonal-antibody-that-blocks-toll-like-receptor-2 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/10/6/first-subject-implanted-in-mainstay-medicals-reactiv8-b-clinical-trial-for-treatment-of-chronic-low-back-pain monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/9/23/mainstay-medical-announces-half-year-financial-results monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/9/20/mainstay-medical-international-plc-reactiv8-a-clinical-trial-sustained-performance-at-one-year monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/9/14/mainstay-medicals-reactiv8-b-clinical-trial-for-treatment-of-chronic-low-back-pain-enrolls-first-subject monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/9/12/inflazome-closes-a-17m-series-a-round-from-novartis-venture-fund-and-fountain-healthcare-partners-to-develop-treatments-for-chronic-inflammatory-diseases monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/9/8/chrono-therapeutics-raises-476-million-in-series-b-financing-to-advance-its-clinical-platform-for-personalized-drug-therapy monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/9/8/vivasure-medical-announces-162m-183m-in-financing-to-advance-commercialization-of-closure-device-in-european-union-and-united-states monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/9/8/neuravi-announces-european-launch-of-embotrap-ii-stent-retriever-for-the-treatment-of-acute-stroke monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/8/17/innocoll-holdings-plc-announces-second-quarter-2016-financial-and-operating-results-and-provides-corporate-update monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/7/25/neuravi-selects-robert-colloton-to-lead-us-commercialization-of-innovative-stent-retriever monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/6/23/innocoll-holdings-plc-announces-the-completion-of-enrollment-in-two-pivotal-phase-3-clinical-trials-of-cogenzia-for-the-treatment-of-diabetic-foot-infections monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/6/17/innocoll-holdings-plc-announces-pricing-of-public-offering-of-ordinary-shares monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/6/17/mainstay-medical-announces-30-million-fundraising monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/6/11/vascepar-icosapent-ethyl-showed-significant-reductions-in-potentially-atherogenic-lipid-parameters-in-statin-treated-patients-with-type-2-diabetes-and-persistent-high-triglycerides monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/5/31/amarin-announces-fda-new-chemical-entity-market-exclusivity-determination-for-vascepar-icosapent-ethyl-capsules monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/5/25/mainstay-medical-achieves-ce-markingfor-reactiv8and-prepares-for-commercial-launch-in-germany monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/5/25/innocoll-announces-xaracoll-bupivacaine-collagen-bioresorbable-implant-meets-primary-endpoint-in-both-pivotal-phase-3-trials-in-postoperative-pain-relief monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/5/3/neuravi-strengthens-patent-portfolio-for-novel-stent-retrievers-with-newly-issued-us-and-european-patents monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/4/21/innocoll-holdings-plc-appoints-lesley-russell-mbchb-mrcp-as-chief-medical-officer monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/4/21/amarin-reaches-target-enrollment-in-cardiovascular-outcomes-study-of-vascepar-in-patients-with-elevated-triglycerides-despite-statin-therapy monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/3/17/innocoll-holdings-plc-announces-fourth-quarter-and-full-year-2015-financial-and-operating-results-and-provides-corporate-update monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/3/7/spark-therapeutics-announces-acquisition-of-genable-technologies monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/4/26/chrono-therapeutics-smoking-cessation-technology-demonstrates-significant-reduction-in-nicotine-cravings monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/2/10/mainstay-medical-full-year-2015-preliminary-results-and-business-update monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2016/1/8/vivasure-medical-receives-ce-mark-for-first-and-only-fully-bioabsorbable-percutaneous-closure-device-for-large-bore-transcatheter-procedures monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/12/17/innocoll-ag-appoints-charles-katzer-as-head-of-manufacturing-and-technical-operations monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/12/16/neuravi-announces-meeting-of-world-stroke-leaders-at-inaugural-clot-summit-2015 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/12/10/innocoll-ag-announces-plan-to-move-corporate-domicile-to-ireland monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/12/4/additional-data-confirm-positive-results-for-clinical-trial-of-reactiv8 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/11/5/neuravi-announces-first-patient-treated-in-international-pivotal-clinical-trial-of-novel-stent-retriever-for-acute-ischemic-stroke monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/11/2/mainstay-medical-applies-for-ce-mark-for-reactiv8 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/10/1/neuravi-announces-european-launch-of-innovative-minimally-invasive-stroke-therapy monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/9/30/neuromod-announces-55-million-in-financing-to-advance-neuromodulation-based-medical-device-to-treat-chronic-tinnitus monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/9/16/innocoll-ag-announces-first-patient-dosed-in-the-xaracoll-matrix-2-phase-3-study-for-the-treatment-of-postoperative-pain monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/9/14/innocoll-ag-announces-departure-of-chief-medical-officer monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/9/2/innocoll-ag-announces-first-patient-dosed-in-the-xaracoll-matrix-1-phase-3-study-for-the-treatment-of-postoperative-pain monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/9/1/neuravi-ltd-appoints-experienced-neurovascular-executive-robert-stern-to-board-of-directors monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/8/31/positive-results-for-mainstay-medicals-clinical-trial-of-reactiv8 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/8/31/mainstay-medical-announces-half-year-financial-results monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/8/26/chrono-therapeutics-receives-second-fast-track-sbir-grant-from-national-cancer-institute-for-patient-individualized-smoking-cessation-therapy monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/8/24/mainstay-medical-secures-15m-debt-financing monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/8/13/innocoll-ag-appoints-rich-fante-as-chief-commercial-officer-and-head-of-business-development monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/8/8/first-amendment-decision-a-win-for-amarin-and-physician-plaintiffs monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/7/15/mainstay-medical-announces-two-additional-us-patents-issued monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/7/1/innocoll-ag-appoints-jose-carmona-as-chief-financial-officer monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/6/30/innocoll-ag-announces-qualified-infectious-disease-product-qidp-designation-for-cogenzia-for-the-adjunctive-treatment-of-moderate-and-severe-diabetic-foot-infection monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/6/22/mainstay-medical-strengthens-board-with-new-independent-director monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/6/17/neuravi-announces-19m-21m-in-financing-to-advance-innovative-minimally-invasive-stroke-therapy monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/6/16/innocoll-ag-announces-first-patient-dosed-in-the-cogenzia-coact-2-phase-3-study-for-the-treatment-of-diabetic-foot-infection monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/5/29/mainstay-medical-gains-approval-to-start-us-clinical-trial-of-reactiv8 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/5/15/innocoll-ag-announces-first-patient-dosed-in-the-cogenzia-coact-1-phase-3-study-for-the-treatment-of-diabetic-foot-infection monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/5/12/mainstay-medical-interim-management-statement monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/4/24/innocoll-ag-announces-pricing-of-follow-on-offering monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/4/1/pivotal-pharmacokinetic-study-of-innocolls-xaracoll-supports-use-of-300-mg-dose-for-phase-3-clinical-studies-in-post-operative-pain monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/3/30/innocoll-ag-secures-eur-25-million-loan-commitment-from-european-investment-bank-eib monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/3/19/innocoll-ag-announces-fourth-quarter-and-full-year-2014-financial-and-operating-results monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/3/19/mainstay-medical-announces-2014-financial-results monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/3/18/innocoll-ag-appoints-james-tursi-md-as-chief-medical-officer monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/3/3/chrono-therapeutics-receives-investment-from-rock-health-to-advance-smartstoptm-smoking-cessation-technology monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/3/2/opsona-therapeutics-ltd-commences-part-b-of-phase-ii-study-of-blocking-toll-like-receptor-2-in-extended-criteria-donor-renal-transplant-recipients-at-high-risk-of-early-graft-dysfunction monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/2/23/opsona-therapeutics-ltd-patent-issued-in-usa-covering-an-antibody-directed-against-toll-like-receptor-2-tlr-2-and-the-use-and-development-thereof monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/1/26/opsona-therapeutics-ltd-initiates-phase-iii-study-in-a-first-in-class-monoclonal-antibody-that-blocks-toll-like-receptor-2 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/1/26/mainstay-medical-applies-to-start-us-clinical-trial-of-reactiv8 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2015/1/9/fountain-healthcare-partners-launches-second-fund monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/12/8/innocoll-ag-appoints-tony-zook-as-chief-executive-officer-as-company-progresses-toward-becoming-a-fully-integrated-commercial-company monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/12/5/sagentia-selected-as-lead-development-partner-for-chrono-therapeutics-wearable-smart-smoking-cessation-device monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/12/5/mainstay-medical-achieves-quality-system-certification monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/11/13/innocoll-ag-announces-third-quarter-2014-financial-and-operating-results monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/11/6/mainstay-medical-interim-management-statement monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/10/22/acorda-therapeutics-completes-acquisition-of-civitas-therapeutics monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/9/10/genable-technologies-ltd-moving-gt038-into-full-development monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/9/2/neuravi-introduces-collaborative-clot-research-initiative-at-esmint-conference-in-september monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/8/27/civitas-therapeutics-files-registration-statement-for-proposed-initial-public-offering monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/8/25/civitas-therapeutics-secures-55-million-in-series-c-financing monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/7/30/innocoll-ag-announces-closing-of-initial-public-offering monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/7/7/mainstay-medical-announces-pre-ide-submission-for-reactiv8-to-fda monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/6/30/mainstay-medical-announces-expansion-of-clinical-trial-of-reactiv8-for-people-with-chronic-low-back-pain-to-belgium monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/6/12/chrono-therapeutics-inventor-of-wearable-smart-smoking-cessation-technology-secures-32-million-in-series-a-financing monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/5/29/mainstay-announces-the-partial-exercise-of-the-over-allotment-option-increasing-the-gross-proceeds-of-the-offer-to-approximately-188m monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/5/7/palyon-medical-and-core-manufacturing-announce-strategic-partnership monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/4/28/civitas-therapeutics-announces-positive-phase-2b-results-for-cvt-301-inhaled-levodopa-for-the-treatment-of-parkinsons-disease monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/4/28/mainstay-medical-international-plc-announcement-of-offer-price-and-number-of-issued-ordinary-shares-on-admission-to-euronext-paris-and-esm monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/4/9/mainstay-medical-announces-intention-to-launch-initial-public-offering-and-list-on-euronext-paris-and-on-the-enterprise-securities-market-of-irish-stock-exchange monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/3/25/spark-therapeutics-and-genable-technologies-announce-collaboration-to-advance-a-gene-therapy-treatment-for-a-rare-form-of-retinitis-pigmentosa monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/3/10/mainstay-medical-begins-clinical-trial-of-reactiv8-for-people-with-chronic-low-back-pain monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/2/2/mainstay-medical-strengthens-board monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/1/29/civitas-therapeutics-appoints-mark-iwicki-president-and-chief-executive-officer monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2014/1/8/civitas-therapeutics-appoints-timothy-s-nelson-as-chairman-of-the-board-of-directors monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2013/11/22/leading-international-blindness-charities-welcome-genables-enhanced-patent-portfolio monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2013/11/12/civitas-therapeutics-extends-cvt-301-patent-protection-into-2032 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2013/10/2/opsona-therapeutics-limited-raises-an-additional-3-million-usd-4-million-from-omnes-capital-in-series-c-extension-resulting-in-a-total-financing-round-of-36-million-usd-486-million monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2013/9/11/civitas-therapeutics-secures-38-million-in-financing monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2013/9/5/civitas-therapeutics-initiates-phase-2b-clinical-study-of-cvt-301-inhaled-l-dopa-for-parkinsons-disease monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2013/6/19/amarin-informed-by-fda-of-october-16th-advisory-committee-date-in-connection-with-supplemental-new-drug-application-snda-for-vascepar monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2013/6/18/civitas-therapeutics-receives-second-grant-for-their-lead-product-cvt-301-from-the-michael-j-fox-foundation-for-parkinsons-research monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2013/5/28/trino-therapeutics-secures-series-a-investment-of-over-9m-12m-for-a-novel-oral-drug-therapy-for-mild-to-moderate-ulcerative-colitis monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2013/5/13/genable-technologies-ltd-appoints-annette-clancy-as-chairman-of-the-board monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2013/5/7/opsona-therapeutics-ltd-initiates-a-phase-ii-study-with-opn-305 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2013/4/29/opsona-therapeutics-limited-raises-33-million-us43-million-oversubscribed-series-c-equity-financing-to-advance-clinical-development-of-its-lead-product-opn-305 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2013/4/19/civitas-therapeutics-announces-positive-phase-2-clinical-results-for-cvt-301-an-inhaled-l-dopa-for-parkinsons-disease monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2013/4/12/designation-by-fda-for-gene-therapy-product-gt308 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2013/2/1/mainstay-medical-appoints-oern-r-stuge-md-as-chairman-of-the-board monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2012/10/16/civitas-therapeutics-to-present-positive-clinical-study-results-for-cvt-301-at-sixth-annual-parkinsons-disease-therapeutics-conference monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2012/9/26/mainstay-medical-completes-200m-153m-oversubscribed-series-b-venture-financing monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2012/9/7/new-chairman-for-irish-venture-capital-association monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2012/9/5/civitas-therapeutics-appoints-bryan-e-stuart-chief-business-officer monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2012/7/11/irish-medical-device-company-neuravi-completes-52m-series-a-financing monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2012/6/15/civitas-therapeutics-initiates-phase-2a-clinical-study-of-cvt-301-an-inhaled-l-dopa-for-parkinsons-disease monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2012/4/17/opsona-therapeutics-announces-the-issuance-of-new-patent-from-the-european-patent-office-epo-covering-the-development-and-use-of-an-antibody-directed-against-toll-like-receptor-tlr-2 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2011/11/29/civitas-therapeutics-announces-award-of-michael-j-fox-foundation-grant-and-lead-drug-candidate-for-parkinsons-disease monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2011/11/11/irelands-genable-technologies-completes-5m-series-b-financing monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2011/9/26/amarin-announces-nda-submission-for-amr101-for-the-treatment-of-patients-with-very-high-triglycerides monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2011/8/10/amarin-announces-agreement-from-fda-on-special-protocol-assessment-for-amr101-outcomes-study monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2011/7/12/civitas-therapeutics-secures-5m-in-financing-accelerating-parkinsons-disease-program monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2011/7/5/opsona-therapeutics-announces-initiation-of-a-phase-1-clinical-trial-with-its-lead-drug monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2011/5/31/amarin-announces-global-supply-network-for-amr101 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2011/5/19/additional-detail-of-successful-marine-phase-iii-trial-to-be-presented-at-the-national-lipid-association-2011-annual-scientific-sessions monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2011/5/19/amarin-sponsored-posters-to-be-presented-today-at-the-national-lipid-association-2011-annual-scientific-sessions monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2011/5/6/dr-leon-hooftman-appointed-chief-medical-officer-as-opsona-therapeutics-transitions-into-the-clinic monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2011/5/6/european-commission-awards-eur-59m-to-opsona-therapeutics-for-clinical-development-of-lead-drug-candidate-opn-305 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2011/5/6/opsona-therapeutics-appoints-chairman-dr-bernd-r-seizinger-as-executive-chairman-dr-mark-heffernan-resigns-as-ceo-but-remains-as-non-executive-director monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2011/4/18/amarins-amr101-phase-3-anchor-trial-meets-all-primary-and-secondary-endpoints monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2011/1/6/amarin-corporation-announces-the-pricing-of-an-underwritten-public-offering monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2010/12/20/cappella-medical-systems-announces-first-placements-of-its-new-dual-marker-sideguard-system monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2010/12/15/amarin-completes-patient-randomization-in-phase-3-anchor-trial monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2010/12/7/cappella-medical-systems-wins-top-medical-technology-industry-awards monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2010/11/29/amarins-amr101-meets-pivotal-phase-3-study-endpoints monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2010/11/18/amarin-corporation-appoints-kristine-peterson-to-board-of-directors monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2010/11/10/amarin-corporation-announces-senior-management-changes monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2010/11/10/amarin-reports-third-quarter-2010-financial-results-and-positively-updates-phase-3-guidance monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2010/11/1/cappella-inc-completed-the-first-tranche-of-a-105-million-series-d-investment monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2010/8/24/luis-malave-joins-palyon-corporation-as-ceo monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2010/8/18/insulet-announces-departure-of-chief-operating-officer monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2010/8/17/amarin-corporation-appoints-colin-w-stewart-as-president-and-chief-executive-officer monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2010/8/10/amarin-reports-q2-2010-results-marine-trial-results-due-early-2011-anchor-trial-50-randomized-conference-call-today monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2010/8/10/amarins-amr101-pivotal-phase-3-marine-clinical-trial-completes-patient-enrollment-and-randomization-trial-guidance-positively-updated monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2010/6/22/eamonn-hobbs-accepts-appointment-as-chairman-of-the-board-of-directors-of-cappella monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2010/6/14/david-blossom-joins-cappella-as-vice-president-commercial-operations monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2010/5/13/amarin-reports-q1-2010-results monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2009/12/2/amarin-corporation-appoints-industry-veteran-joseph-zakrzewski-as-executive-chairman monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2009/11/16/cappella-inc-announces-initiation-of-sideguard-3 monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2009/11/6/amarin-appoints-john-f-thero-as-chief-financial-officer monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2009/10/19/amarin-announces-completion-of-70-million-private-placement monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2009/10/13/amarin-announces-changes-to-its-board-and-management-team monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2009/6/15/cappella-inc-secures-173-million-series-c-investment monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2009/5/19/nextech-venture-participates-in-the-24m-financing-of-palyon-medical monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2009/4/29/palyon-medical-corporation-secures-21-million-series-a-investment monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2009/2/18/opsona-therapheutics-closes-18m-funding monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2008/7/22/amarin-proceeding-to-phase-3-with-amr101-for-hypertriglyceridemia monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2008/5/14/amarin-announces-private-placement-for-up-to-60-million monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/2008/4/29/launch-of-fountain-healthcare-partners-a-life-science-venture-capital-firm monthly 0.5 2025-11-23 https://www.fh-partners.com/news-entries/tag/Nerre+Therapeutics monthly 0.5 https://www.fh-partners.com/news-entries/tag/Neuravi monthly 0.5 https://www.fh-partners.com/news-entries/tag/Trino+Therapeutics monthly 0.5 https://www.fh-partners.com/news-entries/tag/Chrono+Therapeutics monthly 0.5 https://www.fh-partners.com/news-entries/tag/inflazome monthly 0.5 https://www.fh-partners.com/news-entries/tag/Opsona+Therapeutics monthly 0.5 https://www.fh-partners.com/news-entries/tag/Priothera monthly 0.5 https://www.fh-partners.com/news-entries/tag/Velicept monthly 0.5 https://www.fh-partners.com/news-entries/tag/Corteria monthly 0.5 https://www.fh-partners.com/news-entries/tag/Mainstay+Medical monthly 0.5 https://www.fh-partners.com/news-entries/tag/Innocoll monthly 0.5 https://www.fh-partners.com/news-entries/tag/Calypso monthly 0.5 https://www.fh-partners.com/news-entries/tag/Dualyx monthly 0.5 https://www.fh-partners.com/news-entries/tag/Inflazome monthly 0.5 https://www.fh-partners.com/news-entries/tag/Fountain+Healthcare+Partners monthly 0.5 https://www.fh-partners.com/news-entries/tag/Neurent+Medical monthly 0.5 https://www.fh-partners.com/news-entries/tag/Inotrem monthly 0.5 https://www.fh-partners.com/news-entries/tag/Civitas+Therapeutics monthly 0.5 https://www.fh-partners.com/news-entries/tag/Palyon+Medical monthly 0.5 https://www.fh-partners.com/news-entries/tag/Syndesi monthly 0.5 https://www.fh-partners.com/news-entries/tag/Xylocor monthly 0.5 https://www.fh-partners.com/news-entries/tag/inotrem monthly 0.5 https://www.fh-partners.com/news-entries/tag/MMI monthly 0.5 https://www.fh-partners.com/news-entries/tag/Capella+Medical monthly 0.5 https://www.fh-partners.com/news-entries/tag/Vivasure+Medical monthly 0.5 https://www.fh-partners.com/news-entries/tag/Neuromod monthly 0.5 https://www.fh-partners.com/news-entries/tag/Genable+Technologies monthly 0.5 https://www.fh-partners.com/news-entries/tag/Ermium monthly 0.5 https://www.fh-partners.com/news-entries/tag/kandy+Therapeutics monthly 0.5 https://www.fh-partners.com/news-entries/tag/Amarin monthly 0.5 https://www.fh-partners.com/portfolio daily 0.75 2026-01-20 https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1463023410701-PXUNSWZ9MDIS1AJGT9P3/iStock_000054340724_reduced.jpg Portfolio Frank has trouble remembering things. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1463023433524-9AMSHALUOCNIR98RJ52P/iStock_000028090504_reduced.jpg Portfolio Jeff needs his back pain to go away. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/3f832e79-6c3e-4a95-abf2-3c2c2d724bdd/iStock_000057074882_reduced.png Portfolio Martha needs to recover from her stroke. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1463023478703-CH6U2K7YT0HKP3XV4UCC/iStock_000078497143_reduced.jpg Portfolio Susan needs to stop the ringing in her ears. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1568295180379-T1VNDEC53WYKX7S7N8Q7/Smaller+Icon4.png Portfolio https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1581431967174-9F497JH8W9ZWKJXN80UE/image-asset.png Portfolio Inotrem has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1631823355491-G1GP3GLLUYW07QHEKUDI/Mainstay+new.png Portfolio Mainstay Medical (MSTY) is commercializing an implantable neurostimulation system for people with disabling Chronic Low Back Pain (CLBP). https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1631199179005-5Q3XUV4K3QGVBO0ZK2K0/Calypso.png Portfolio - Make it stand out Calypso Biotech is an immunotherapy biotech company, spin-off from Merck Serono, that discovers and develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs. Novartis acquired Calypso in Jan 2024 for up to $425M https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/9f434ee9-7a22-4787-8f6e-5a6f51066cf9/Ermium.png Portfolio - Make it stand out Ermium Therapeutics is a biotech company developing functionally selective immunomodulators targeting CXCR4 for auto-immune disease indications, particularly interferonopathies, including SLE. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1603223647959-R8EK6UYYPDAIOK86TJTH/PRIOTHERA+Logotype.png Portfolio Priothera is developing an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in patients https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1616422536855-XK6SA8U8EMILYHYPSO46/XyloCor.png Portfolio XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/261a1187-d2ba-4440-b121-03af99227f49/Corteria.png Portfolio - Make it stand out Corteria Pharmaceuticals is a spin off biotech company from Sanofi developing first-in-class drugs for the treatment of distinct heart failure subpopulations. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/8f9f4521-0de9-4639-b777-84ab991ba4b2/Dualyx.png Portfolio - Make it stand out Dualyx is a Belgium-based biotech company dedicated to the development of novel Treg based therapies to address the needs of patients with difficult-to-treat autoimmune diseases. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461195397783-O79HO5S40PTHDEE4AH4S/image-asset.png Portfolio https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1473712477995-6R3WFCC6YUBYV1QLJ5YA/image-asset.png Portfolio Chrono developed a biologically timed transdermal drug delivery system with a behavioral support delivered via an app to help people manage hard-to-treat conditions. Their first application was smoking cessation. The company ceased operations in 2019. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1466176240786-I7PI2KH6N3WGIT0I7Y1U/image-asset.png Portfolio Using a proprietary collagen-based technology, Innocoll is developing a portfolio of products to treat post-operative pain and prevent post-surgical adhesions. Innocoll was listed on NASDAQ as INNL prior to its acquisition by Gurnet Point in 2017 https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1517558159618-7156FL40FH61GPRO7YTE/Neuromod-Logo-for-Fountain-1080x200.jpg Portfolio Using neuromodulation treatments, Neuromod is helping people with chronic and often debilitating tinnitus, informally called "ringing in the ears." https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1473712019452-AMZEC3H4MIIQWYJ77IKA/image-asset.png Portfolio Inflammasomes generate signals that cause immune cells to fight infections. Inflazome is developing novel treatments for inflammation-related diseases by precisely blocking unwanted inflammasome signals. Inflazome was sold to Roche Pharmaceuticals in 2020 for an upfront consideration of €380M and additional consideration in the form of milestone payments. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1483621094847-11EJOGAQCW7FC83SV0HR/NerreThera.png Portfolio Developing a unique portfolio of neurokinin (NK) receptor antagonists, NeRRe Therapeutics is aiming to treat common debilitating respiratory and women's health conditions caused by neuronal hypersensitivity. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1492751409691-MVTVKIOK9Z0ORK4Z2UU8/image-asset.png Portfolio Velicept was developing solabegron, a highly differentiated B3 agonist for overactive bladder (OAB) and irritable bowel syndrome (IBS). The company ceased operations in 2020. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1506462113915-PIH67GNWKWQLVO4F276M/image-asset.png Portfolio KaNDy Therapeutics was a UK based clinical-stage company focused on developing NT-814, a first-in-class, once daily, dual mechanism neurokinin-1,3 receptor antagonist. The medicine is being developed as a non-hormonal alternative to hormone replacement therapy for the treatment of postmenopausal symptoms (PMS). KaNDy was sold to Bayer Pharmaceuticals in 2020 for $425M up front and additional consideration in the form of milestone payments. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1524575312325-TDJJ0CON44PFZYWTVW5M/MMI+Portfolio.png Portfolio Medical Microinstruments S.r.l. (MMI) is developing a novel robotic platform specifically designed for open microsurgery. The platform allows the surgeon to control two tiny articulated microinstruments that offer motion scaling and tremor elimination, improving surgical success rates and patient outcomes. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1519882819465-2UKYAFV5KLZWQOIOZVX9/Syndesi.png Portfolio Syndesi Therapeutics was developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission. Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi was sold to Abbvie in 2022 for $130M up front and additional consideration of up to $870M based on achievement of development and commercial milestones https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1614633711610-TL06JZMS2OC500EHUPX7/Neurent+v.png Portfolio Neurent Medical is developing a device to treat inflammatory diseases of the nasal cavities. The initial product offering reduces the primary symptoms of rhinitis, congestion and rhinorrhoea. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461195414893-MHUYWH140HDQNQ1DQSGI/image-asset.png Portfolio https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461192932811-NTPJGKQHW3QNJ7S5BI1J/image-asset.png Portfolio With extensive experience in lipid science, Amarin is commercializing Vascepa, a novel therapeutic for the prevention and treatment of cardiovascular disorders. Fountain has exited this investment. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461192979590-PSN14N1MOM3C5XQH2UPR/image-asset.png Portfolio Before being acquired by Acorda Therapeutics for $525M in cash in October 2014, Civitas was applying its dry powder inhalation drug delivery technology to Parkinson’s treatments. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461194776074-EANBDT4UD16P4N1PJ1WV/image-asset.png Portfolio Genable developed a gene therapy platform to suppress and replace genes associated with Retinitis Pigmentosa. The company was acquired by Spark Therapeutics in March 2016. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1462293859318-7VZD3POOQ5T70OXVLZH5/image-asset.png Portfolio With a portfolio of unique interventional neurovascular devices, Neuravi is improving clinical outcomes for stroke patients. Johnson & Johnson acquired the company in March 2017. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461193451784-VKG9EW6QPCZM2D23Y251/image-asset.png Portfolio Mainstay Medical (MSTY) is commercializing an implantable neurostimulation system for people with disabling Chronic Low Back Pain (CLBP). https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461193383586-O8K60S1AZMWWK8C21L7O/image-asset.png Portfolio Targeting the human immune system, Opsona developed drugs with wide applicability to conditions such as autoimmune and inflammatory diseases, solid organ transplantation and oncology. The company ceased operations in 2019. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461193666740-LYFQB82NP9F4FQE8IOEG/image-asset.png Portfolio Aiming to help people undergoing vascular surgery, Vivasure Medical has developed a bioabsorbable technology delivered percutaneously to assist in vessel closure. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461206008263-E4HXS5MPUGQUBSGBINRR/image-asset.png Portfolio Cappella built and distributed a bifurcation stent to protect coronary sidebranch arteries during cardiac procedures. Now called ArraVasc Limited, they are focused on peripheral vascular products. This investment is inactive. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461193413341-UEXJ6VZEJ2BQSRX4R7VD/image-asset.png Portfolio Leveraging oral small molecules, Trino Therapeutics was focused on treating and managing inflammatory indications such as inflammatory bowel disease (IBD). The company ceased operations in 2017. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461194416647-WD8MXBILCB9SUT7YD5T0/image-asset.png Portfolio With an implantable infusion pump, Palyon Medical was treating chronic pain, spasticity and diseases of the central nervous system. The company ceased operations in 2015. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1568295180379-T1VNDEC53WYKX7S7N8Q7/Smaller+Icon4.png Portfolio - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/3de9d668-ef90-44df-81af-547a0fc43d4d/Exciva.png Portfolio - Make it stand out Exciva is developing a groundbreaking therapy that effectively and safely addresses neuropsychiatric symptoms of dementia including agitation/aggression in Alzheimer’s disease dementia https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1568295180379-T1VNDEC53WYKX7S7N8Q7/Smaller+Icon4.png Portfolio https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1581431967174-9F497JH8W9ZWKJXN80UE/image-asset.png Portfolio Inotrem has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1631823355491-G1GP3GLLUYW07QHEKUDI/Mainstay+new.png Portfolio Mainstay Medical (MSTY) is commercializing an implantable neurostimulation system for people with disabling Chronic Low Back Pain (CLBP). https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1631199179005-5Q3XUV4K3QGVBO0ZK2K0/Calypso.png Portfolio - Make it stand out Calypso Biotech is an immunotherapy biotech company, spin-off from Merck Serono, that discovers and develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs. Novartis acquired Calypso in Jan 2024 for up to $425M. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/9f434ee9-7a22-4787-8f6e-5a6f51066cf9/Ermium.png Portfolio - Make it stand out Ermium Therapeutics is a biotech company developing functionally selective immunomodulators targeting CXCR4 for auto-immune disease indications, particularly interferonopathies, including SLE. The company ceased operations in 2024. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1603223647959-R8EK6UYYPDAIOK86TJTH/PRIOTHERA+Logotype.png Portfolio Priothera is developing an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in patients https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1616422536855-XK6SA8U8EMILYHYPSO46/XyloCor.png Portfolio XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/261a1187-d2ba-4440-b121-03af99227f49/Corteria.png Portfolio - Make it stand out Corteria Pharmaceuticals is a spin off biotech company from Sanofi developing first-in-class drugs for the treatment of distinct heart failure subpopulations. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/8f9f4521-0de9-4639-b777-84ab991ba4b2/Dualyx.png Portfolio - Make it stand out Dualyx is a Belgium-based biotech company dedicated to the development of novel Treg based therapies to address the needs of patients with difficult-to-treat autoimmune diseases. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461195397783-O79HO5S40PTHDEE4AH4S/image-asset.png Portfolio https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1473712477995-6R3WFCC6YUBYV1QLJ5YA/image-asset.png Portfolio Chrono developed a biologically timed transdermal drug delivery system with a behavioral support delivered via an app to help people manage hard-to-treat conditions. Their first application was smoking cessation. The company ceased operations in 2019. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1466176240786-I7PI2KH6N3WGIT0I7Y1U/image-asset.png Portfolio Using a proprietary collagen-based technology, Innocoll is developing a portfolio of products to treat post-operative pain and prevent post-surgical adhesions. Innocoll was listed on NASDAQ as INNL prior to its acquisition by Gurnet Point in 2017 https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1517558159618-7156FL40FH61GPRO7YTE/Neuromod-Logo-for-Fountain-1080x200.jpg Portfolio Using neuromodulation treatments, Neuromod is helping people with chronic and often debilitating tinnitus, informally called "ringing in the ears." https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1473712019452-AMZEC3H4MIIQWYJ77IKA/image-asset.png Portfolio Inflammasomes generate signals that cause immune cells to fight infections. Inflazome is developing novel treatments for inflammation-related diseases by precisely blocking unwanted inflammasome signals. Inflazome was sold to Roche Pharmaceuticals in 2020 for an upfront consideration of €380M and additional consideration in the form of milestone payments. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1483621094847-11EJOGAQCW7FC83SV0HR/NerreThera.png Portfolio Developing a unique portfolio of neurokinin (NK) receptor antagonists, NeRRe Therapeutics is aiming to treat common debilitating respiratory and women's health conditions caused by neuronal hypersensitivity. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1492751409691-MVTVKIOK9Z0ORK4Z2UU8/image-asset.png Portfolio Velicept was developing solabegron, a highly differentiated B3 agonist for overactive bladder (OAB) and irritable bowel syndrome (IBS). The company ceased operations in 2020. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1506462113915-PIH67GNWKWQLVO4F276M/image-asset.png Portfolio KaNDy Therapeutics was a UK based clinical-stage company focused on developing NT-814, a first-in-class, once daily, dual mechanism neurokinin-1,3 receptor antagonist. The medicine is being developed as a non-hormonal alternative to hormone replacement therapy for the treatment of postmenopausal symptoms (PMS). KaNDy was sold to Bayer Pharmaceuticals in 2020 for $425M up front and additional consideration in the form of milestone payments. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1524575312325-TDJJ0CON44PFZYWTVW5M/MMI+Portfolio.png Portfolio Medical Microinstruments S.r.l. (MMI) is developing a novel robotic platform specifically designed for open microsurgery. The platform allows the surgeon to control two tiny articulated microinstruments that offer motion scaling and tremor elimination, improving surgical success rates and patient outcomes. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1519882819465-2UKYAFV5KLZWQOIOZVX9/Syndesi.png Portfolio Syndesi Therapeutics was developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission. Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi was sold to Abbvie in 2022 for $130M up front and additional consideration of up to $870M based on achievement of development and commercial milestones https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1614633711610-TL06JZMS2OC500EHUPX7/Neurent+v.png Portfolio Neurent Medical has developed Neuromark, an innovative, clinically proven procedure designed to safely target the root cause of CR—overactive posterior nasal nerves (PNN). By using low-power energy to disrupt these nerves, NEUROMARK provides durable relief from persistent symptoms https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461195414893-MHUYWH140HDQNQ1DQSGI/image-asset.png Portfolio https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461192932811-NTPJGKQHW3QNJ7S5BI1J/image-asset.png Portfolio With extensive experience in lipid science, Amarin is commercializing Vascepa, a novel therapeutic for the prevention and treatment of cardiovascular disorders. Fountain has exited this investment. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461192979590-PSN14N1MOM3C5XQH2UPR/image-asset.png Portfolio Before being acquired by Acorda Therapeutics for $525M in cash in October 2014, Civitas was applying its dry powder inhalation drug delivery technology to Parkinson’s treatments. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461194776074-EANBDT4UD16P4N1PJ1WV/image-asset.png Portfolio Genable developed a gene therapy platform to suppress and replace genes associated with Retinitis Pigmentosa. The company was acquired by Spark Therapeutics in March 2016. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1462293859318-7VZD3POOQ5T70OXVLZH5/image-asset.png Portfolio With a portfolio of unique interventional neurovascular devices, Neuravi is improving clinical outcomes for stroke patients. Johnson & Johnson acquired the company in March 2017. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461193451784-VKG9EW6QPCZM2D23Y251/image-asset.png Portfolio Mainstay Medical (MSTY) is commercializing an implantable neurostimulation system for people with disabling Chronic Low Back Pain (CLBP). https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461193383586-O8K60S1AZMWWK8C21L7O/image-asset.png Portfolio Targeting the human immune system, Opsona developed drugs with wide applicability to conditions such as autoimmune and inflammatory diseases, solid organ transplantation and oncology. The company ceased operations in 2019. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461193666740-LYFQB82NP9F4FQE8IOEG/image-asset.png Portfolio Aiming to help people undergoing vascular surgery, Vivasure Medical has developed a bioabsorbable technology delivered percutaneously to assist in large vessel closure. The company was acquired by Haemonetics (NYSE:HAEM) in January 2026 for up to €185M, €100M of which was paid on closing. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461206008263-E4HXS5MPUGQUBSGBINRR/image-asset.png Portfolio Cappella built and distributed a bifurcation stent to protect coronary sidebranch arteries during cardiac procedures. Now called ArraVasc Limited, they are focused on peripheral vascular products. This investment is inactive. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461193413341-UEXJ6VZEJ2BQSRX4R7VD/image-asset.png Portfolio Leveraging oral small molecules, Trino Therapeutics was focused on treating and managing inflammatory indications such as inflammatory bowel disease (IBD). The company ceased operations in 2017. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461194416647-WD8MXBILCB9SUT7YD5T0/image-asset.png Portfolio With an implantable infusion pump, Palyon Medical was treating chronic pain, spasticity and diseases of the central nervous system. The company ceased operations in 2015. https://www.fh-partners.com/team daily 0.75 2025-12-17 https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1463023323422-2WCNAFGWQSEJ4FT6JY39/iStock_000000881721_reduced.jpg Team https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1471922226964-M4P7DAJ1XJWAETUOIKNR/image-asset.png Team https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1559758164885-MMD1URXOLSQBSXG3510Z/Aidan2_headshot.png Team https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1471922466460-FFL6UMKE50PVQE7C17IX/image-asset.jpeg Team https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/b978b929-8dff-4942-920a-4d30f44d6732/RM.jpg Team - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1558739205213-Q5E54LAN2RYYIVDNTSAJ/Tania_headshot.jpg Team https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/bab2b95b-2e7a-4bc9-abc1-24160cd68fac/CT+Headshot.jpg Team - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/6f1a6fff-dee7-4f0b-8915-3306942a5836/Ena+High+Res_PAU11142_1.jpg Team - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1559758535013-MCCIZBZLKZS5M8GN7ER0/Justin_headshot.png Team - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/c332a8af-de24-477d-9472-87450b9a26c9/AF_1+High+res.jpg Team - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1471922226964-M4P7DAJ1XJWAETUOIKNR/image-asset.png https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1559758164885-MMD1URXOLSQBSXG3510Z/Aidan2_headshot.png https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/b978b929-8dff-4942-920a-4d30f44d6732/RM.jpg https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1558739205213-Q5E54LAN2RYYIVDNTSAJ/Tania_headshot.jpg https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/bab2b95b-2e7a-4bc9-abc1-24160cd68fac/CT+Headshot.jpg https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/6f1a6fff-dee7-4f0b-8915-3306942a5836/Ena+High+Res_PAU11142_1.jpg https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1559758535013-MCCIZBZLKZS5M8GN7ER0/Justin_headshot.png https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/c332a8af-de24-477d-9472-87450b9a26c9/AF_1+High+res.jpg https://www.fh-partners.com/submit-plan daily 0.75 2016-04-25 https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461602007782-FFGEAHW7WGG7XBM6CGC6/stock-photo-57196602-light-bulbs.jpg Submit Plan https://www.fh-partners.com/news daily 0.75 2025-11-22 https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1463023369948-XZYZU3K55OEGPT30AMIT/iStock_000010682054_reduced.jpg News https://www.fh-partners.com/privacy daily 0.75 2023-10-27 https://www.fh-partners.com/home-headshots daily 0.75 2025-11-23 https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1463023410701-PXUNSWZ9MDIS1AJGT9P3/iStock_000054340724_reduced.jpg Patient Headshots Frank has trouble remembering things. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1463023433524-9AMSHALUOCNIR98RJ52P/iStock_000028090504_reduced.jpg Patient Headshots Jeff needs his back pain to go away. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1463023454693-1S8POO4P4WG36Q8XB2N1/iStock_000057074882_reduced.jpg Patient Headshots Martha needs to recover from her stroke. https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1463023478703-CH6U2K7YT0HKP3XV4UCC/iStock_000078497143_reduced.jpg Patient Headshots Susan needs to stop the ringing in her ears. https://www.fh-partners.com/home daily 1.0 2026-03-23 https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461195414893-MHUYWH140HDQNQ1DQSGI/image-asset.png https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461195414893-MHUYWH140HDQNQ1DQSGI/image-asset.png https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461195414893-MHUYWH140HDQNQ1DQSGI/image-asset.png https://images.squarespace-cdn.com/content/v1/56fd4fc09f726631f41fd683/1461195414893-MHUYWH140HDQNQ1DQSGI/image-asset.png